Myc genes are a family of proto-oncogenes whose proteins are implicated in the regulation of cell proliferation, differentiation and apoptosis, and in regulating the activity of genes involved in cell division. The aim of the present study was to establish a quantitative description of the expression of c-myc and evaluate its relationship with other clinical and prognostic factors, as well as to establish a multivariate survival prediction model. This is a retrospective study of 68 patients diagnosed with oral squamous cell carcinoma (OSCC). We constructed a tissue microarray for investigating the expression of c-myc by immunohistochemistry. Statistical analyses were carried out, and a multivariate model that predicts survival was established. The average expression of c-myc was 50.32 (SD, 26.05) with a range from 6.60 to 99.
Introduction
An oral squamous cell carcinoma (OSCC) is a tumor characterized by multiple multistep genetic alterations, that lead to genomic instability and disordered cell growth due to oncogene overexpression, subexpression of tumor-suppressor genes and other genetic, epigenetic and microRNA alterations (1) (2) (3) (4) (5) . The two most studied oncogenes (dominant) in human solid tumors are HER-2/neu and c-myc; while p53 is a tumor-suppressor gene involved in almost all human malignancies (6) .
Myc genes are a family of proto-oncogenes comprised of several members (L-myc, N-myc and c-myc). Myc proteins are involved in the regulation of cell proliferation, differentiation and apoptosis, and in regulating the activity of genes involved in cell division (7) . Contrary to classical theory, c-myc is also implicated in the control of apoptotic phenomena, possibly leading to tumor regression depending on cell type, cell interactions, extracellular matrix and neighboring cells (3, 8, 9) . The c-myc protein acts as a transcription factor (10) , and ectopic expression of this protein is sufficient to induce the progression of the cell cycle. c-myc is also related to a poor tumor prognosis (11) (12) (13) (14) as well as the self-renewal of tumor stem cells (15) (16) (17) (18) .
The aim of the present study was to establish a quantitative description of the expression of c-myc and to evaluate its relationship with clinical and prognostic factors of OSCC, as well as to establish a multivariate survival prediction model.
Materials and methods

Patients.
We performed an observational study on a cohort of 68 patients diagnosed with OSCC who were surgically treated Tissue microarray generation. Hematoxylin and eosin-stained (H&E) slides were available for review in all cases. Paraffin blocks were selected on the basis of the availability of suitable formalin-fixed, paraffin-embedded tissue (at least 1-mm thick). For characterization of immunohistochemical protein expression, we constructed five different tissue arrays containing representative areas of every tumor. After microscopic evaluation, two areas of each tumor were selected, avoiding necrosis and keratin pools. Each tissue array was assembled as previously described (20) . Briefly, two 1.5-mm-diameter cylinders of tissue were obtained from representative areas of each archival paraffin block and arrayed into a new recipient paraffin block with a custom-built precision instrument (Beecher Instruments, Silver Spring, MD, USA). These tissues were fixed in 4% buffered formalin and were paraffin-embedded according to routine procedures. Areas chosen for the cylinder core were representative of the tumors. In addition, normal tonsil samples were placed adjacent to the tumoral tissues to serve as internal controls and to ensure the quality of staining in the slides. Initial sections were stained with hematoxylin and eosin to verify histopathologic findings.
Immunohistochemistry. Tissue sections (3-µm) from the TMA blocks were sectioned and applied to special immunohistochemistry coated slides (Dako, Glostrup, Denmark). Immunohistochemical analysis for c-myc was performed using a monoclonal antibody (clone 9E11; Novocastra, Newcastle, UK) with a concentration 1:100, according to the manufacturer's instructions. In brief, antigen retrieval was performed for 10 min at 95-99˚C in a water bath, with a citrate buffer, pH 9.0. After blocking endogenous peroxidase activity, the slides were incubated for 30 min with the c-myc antibody. A secondary antibody reagent (polymer-based goat anti-mouse antibody fragment conjugated to horseradish peroxidase) was applied for 30 min. After applying the chromogenic visualization step using the 3,3'-diaminobenzidine chromogen, slides were counterstained with hematoxylin. Negative controls were performed using the negative reagent control (isotype control antibody). Dysplasia was graded as mild, moderate, severe and carcinoma 'in situ', according to the criteria of the WHO (21) .
Evaluation of immunohistochemical results, image digitizing and semiquantitative analysis.
Cases showing cytoplasmic or nuclear positivity for c-myc were considered as positive. Slides were digitized using an automated slide scanner to produce high-resolution images for visual quantitative analysis using an ACIS ® III automatic image analysis system (Dako). The digital images of the slides were captured by the ACIS scanner at low power magnification, and the entire slide images were viewed on a monitor. The regions with the highest immune percentage of positive cells were selected for further automatic scoring. A minimum of three of these areas containing only tumor cells was selected manually for quantitative evaluation. The final score was the average result of the different areas measured. To confirm the accuracy of the measurements, selected areas from 10 of the specimens were measured three times.
Statistical analysis. Qualitative variables are expressed as frequencies and percentages; quantitative variables are expressed as means (standard deviation) and ranges. The χ 2 test or Fisher's exact test was used as required to compare the qualitative variables. ANOVA or the Kruskal-Wallis test was used to contrast quantitative and qualitative variables. An association was considered statistically significant when the P-value was ≤0.05. The Kaplan-Meier method/estimator and the Cox regression model were used for evaluating survival in the study sample.
Initially, we carried out a univariate analysis in which we studied the Kaplan-Meier curves of each of the categorical/ qualitative variables to assess if we detected differences in the survival between the different groups or levels of these variables. Subsequently, we adjusted the Cox regression univariate models to assess the influence of each of the analyzed variables on the survival prognosis.
A time-dependent multivariate Cox regression mode was fitted to jointly evaluate the possible risk factors in terms of survival. The recurrence of the patients was considered as the time-dependent covariate. The predictive multivariate analysis/model was performed using a stepwise procedure in terms of the best (the lowest) Akaike Information Criterion (AIC) value. The magnitude of the association between covariates and survival was evaluated through hazard ratios (HR), together with their corresponding 95% confidence intervals (CI). Taking censored survival times into account, the log hazard ratios of the Cox model were used as criterion variables Y, to construct time-dependent ROC curves (22) .
All statistical analyses were conducted using SPSS Statistics 17.0 and R 2.15.0 (R Development Core Team, 2012), using the survival package (for fitting parametric Cox regression models), the survivalROC package (for computing time-dependent ROC curves) and the censboot function (from the bootstrap package) for bootstrapping survival models with censored observations. The function stepAIC (from the MASS package) was also used for obtaining the multivariate model with the best AIC. All these packages are freely available at http://www.R-project.org.
Results
Clinical, anatomical and pathological characteristics of the sample. The main clinical characteristics of the 68 patients selected for the present study are documented in Table I . Tumors were classified into initial stage (stages I and II), which accounted for 32 cases (47.8%), and advanced stage (stages III and IV), which amounted to 36 cases (52.9%). More men were diagnosed in early tumor stages [21 (65.6%)], whereas women were found more frequently in advanced stages at the time of initial diagnosis [22 (61.1%)] (χ 2 =4.848, P<0.05). In terms of the relationship with exposure to tobacco, no statistically significant differences in terms of staging at the time of diagnosis (χ 2 =1.227, P=0.541) were noted. In regards to alcohol, of the 22 cases exposed to the carcinogen, 16 (72.7%) were diagnosed in early stages (χ 2 =11.338, P<0.01). The existence of dysplasia in the adjacent margin was positive in 42.6% of cases; 34.4% of the tumors in initial stages and 50% of the tumors in advanced stages (χ 2 =2.176, P=0.337). The existence of CIS was slightly higher in advanced stage tumors [9 (25%)] in contrast to 21.9% found in initial cases, although the differences were not statistically significant.
c-myc expression in OSCC.
Immunohistochemistry showed both nuclear and cytoplasmic staining in neoplastic cells, while in many cases, the intensity was higher in the cytoplasm than that in the nuclei (Fig. 1) .
The average expression of c-myc (N=53) was 50. of c-myc and any other clinical or pathological parameters (Table I) .
Survival and follow-up analysis.
The average follow-up was 33.5 months (CI, 28.23-40.38). Of the 36 (52.9%) patients who died, 24 (66.7%) were in the advanced stage group at the time of diagnosis (χ 2 =5.785, P<0.05). The average survival of the sample was 50.52 months (95% CI, 41.07-59.96); according to the Kaplan-Meier curve, the cases at the initial stages had a higher survival rate (40.72 months) than those in advanced stages (28.6 months) and the differences were statistically significant (P<0.01) (Fig. 2A) . Recurrence occurred in 39 cases (57.4%) during the follow-up period, regardless of the tumor stage at the time of diagnosis (χ 2 =0.30, P=1.000). We detected statistically significant differences in the survival of patients with recurrence in contrast with those who did not relapse, showing a lower overall survival rate in the recurrence group (P<0.01) (Fig. 2B) . Survival was also statistically significantly reduced in patients with any degree of dysplasia in the adjacent margin, in contrast with those who did not have dysplasia (P<0.05).
The Cox univariate regression analysis verified that the effect of the value of c-myc alone was not statistically significant (P=0.735). In a multivariate Cox analysis, however, the multivariate with the lower ACI obtained included the covariates: recurrence, c-myc, gender, location, differentiation, stage, size, alcohol consumption, dysplasia in the adjacent margin, interaction between c-myc and recurrence, and the interaction between gender and stage (ACI=155.0655). All of the variables were statistically significant, except for gender, stage and dysplasia in the adjacent margin. Gender and stage were not significant, but their relevant interactions were (Table II) . Using this model, we observed that patients with recurrence had a 8303.37-fold higher risk than those without recurrence (P<0.01; HR, 8303.37; 95% CI, 34.30-2010000). For each unit of increase of c-myc, the risk increased by 1.15 (P<0.001; HR, 1.150; 95% CI, 1062-1245). Patients with tumors located in the gum presented a 278.86-fold higher risk (P<0.001; HR, 278.86; 95% CI, 13.76-5653), followed by tumors in the tongue, with a risk of 16.24 (P<0.05; HR, 16.24; 95% CI, 1.37-193) when compared to tumors located in the buccal mucosa. Patients with moderate differentiation presented a risk 8.87-fold higher (P<0.01; HR, 8.87; 95% CI, 2.01-39.13) than those with welldifferentiated tumors. We found the same results for poorly differentiated tumors, which showed a risk 7.48-fold higher (P<0.05; HR, 7.48; 95% CI, 1.06-52.73). In patients who were former drinkers, the risk decreased by 0.02 (P<0.001; HR, 0.02; 95% CI, 0.02-0.19).
Temporary AUC showed an approximate mean value of 0.9 for the follow-up between 35 months and the end of the followup period, which indicates a good discrimination capacity of the Cox model (Fig. 3) .
Discussion
The influence of c-myc in the carcinogenic process, in general, has been previously described in many tumors. In the specific case of oral tumors, Goessel et al (23) developed a cellular model of oral-esophageal carginogenesis, in which cyclin D1 (24, 25) .
Several studies have analyzed c-myc expression in this type of tumor showing different results, with an average positivity of 41.28% (2.4-75%) between the different studies (6, (26) (27) (28) (29) (30) (31) (32) (33) (34) . The results are extremely contradictory, as well as the variation in the quantification methods. In the present study we effectively developed a quantitative evaluation.
Shah et al (6) found a significantly higher expression in T3/T4 tumors in comparison with T1/T2 tumors, although we were unable to verify this fact in our research. On the other hand, c-myc was correlated with tumor stage and lymphatic permeation, while in our study the expression was practically the same. Rodrigo et al (35) found no relationship between c-myc overexpression and tumor prognosis, similar to Hayry et al (33) . Baral et al (27) found that tumors with positive p53 and c-myc were in the advanced stages of the disease (poorly differentiated, stage III), while OSCCs in early stages did not show positive immonoreactivity for p53 and c-myc.
Eversole and Sapp (36) studied c-myc levels in precancerous lesions and early cancerous lesions, and found that, in cases of dysplasia, in situ carcinoma and carcinoma, c-myc nuclear tinting was dominant in all the strata harboring atypical cells and the degree of tinting increased as the levels of atypia were higher. Shah et al (30) described an odds ratio (OR) of 6 in the transformation from hyperplasia to dysplasia, for c-myc (+) lesions and an OR of 3 for progressions beyond early stage carcinoma.
Vora et al (28) , in a multivariate analysis, found that c-myc multiexpression is a clear indicator of poor prognosis, which can be used to evaluate specimens, paired with clinical staging, to determine locally advanced tumors. However, Tsuzuki et al (37) , found no correlation between c-myc and 5-year survival of patients with oral and oropharangeal carcinomas. In our multivariate model, the increase in c-myc levels was positively statistically correlated with the risk of death.
The role of c-myc in carcinogenesis has been well described; however, its relationship with OSCC and clinical and pathological variables of tumors is not entirely clear. Thus, further study of this protein, which may have significant diagnostic, prognostic and therapeutic value is warranted. The determination of c-myc can be valuable when used together with other markers to assess the prognosis of OSCC patients. 
